Edition:
United States

Abbott Laboratories (ABT)

ABT on New York Consolidated

59.31USD
19 Jan 2018
Change (% chg)

$0.24 (+0.41%)
Prev Close
$59.07
Open
$59.23
Day's High
$59.68
Day's Low
$58.96
Volume
7,363,008
Avg. Vol
5,967,485
52-wk High
$59.68
52-wk Low
$39.25

Latest Key Developments (Source: Significant Developments)

Mylan To Complete $1 Billion Share Repurchase Plan
Monday, 8 Jan 2018 07:30am EST 

Jan 8 (Reuters) - Mylan Nv ::MYLAN TO COMPLETE $1 BILLION SHARE REPURCHASE PLAN.MYLAN - AS PER AGREEMENT WITH ABBOTT RELATED TO ABBOTT EPD DEAL, ABBOTT NOTIFIED MYLAN IT SOLD REMAINING 20.3 MILLION IN MYLAN SHARES PRIOR TO YEAR-END​.  Full Article

Abbott gets New FDA Labeling For Some Of Its MRI-Ready Devices
Wednesday, 3 Jan 2018 09:00am EST 

Jan 3 (Reuters) - Abbott Laboratories ::NEW FDA MR-CONDITIONAL LABELING APPROVALS FURTHER EXPAND ABBOTT'S PORTFOLIO OF MRI-READY DEVICES.  Full Article

Abbott Increases Quarterly Dividend To 28 Cents Per Share
Friday, 15 Dec 2017 10:17am EST 

Dec 15 (Reuters) - Abbott Laboratories ::ABBOTT LABORATORIES - INCREASED COMPANY'S QUARTERLY COMMON DIVIDEND TO 28 CENTS PER SHARE FROM 26.5 CENTS PER SHARE.  Full Article

Abbott gets FDA clearance for its Alinity ci-series instruments
Tuesday, 31 Oct 2017 09:00am EDT 

Oct 31 (Reuters) - Abbott Laboratories :Abbott announces FDA clearance for its Alinity ci-series next-generation diagnostic systems.Abbott laboratories - ‍secured U.S. FDA 510(k) clearance for its alinity ci-series instruments for clinical chemistry and immunoassay diagnostics​.  Full Article

Abbott says ‍secured FDA clearance for confirm Rx Insertable Cardiac Monitor​
Monday, 23 Oct 2017 09:00am EDT 

Oct 23 (Reuters) - Abbott Laboratories :Abbott - ‍secured FDA clearance for confirm Rx Insertable Cardiac Monitor​.  Full Article

Abbott CFO says Alere is expected to contribute around $475 mln to reported sales this year
Wednesday, 18 Oct 2017 10:41am EDT 

Oct 18 (Reuters) - Abbott Laboratories :Abbott CFO says Alere, is expected to contribute around $475 million to reported sales, and forecast a neutral impact on adjusted earnings per share this year - Conf Call.Abbott CFO expects fourth quarter adjusted earnings per share of $0.72 to $0.74 - Conf Call.Abbott CFO expects Q4 comparable operational sales growth in the mid to high single-digits - Conf Call.Abbott CFO says "established pharmaceuticals, we forecast double-digit sales growth and in nutrition, we forecast low single-digit sales growth" in Q4 - Conf Call.Abbott CFO says "in diagnostics, we forecast sales to increase mid single-digits and in medical devices, we forecast sales to increase mid to high single-digits in Q4" - Conf Call.Abbott CEO on China nutrition business says "we've seen a stabilizing of China, it hasn't been as choppy as it was in the last 2 years".  Full Article

Abbott Q3 adjusted EPS $0.66 from continuing operations
Wednesday, 18 Oct 2017 07:45am EDT 

Oct 18 (Reuters) - Abbott Laboratories ::Abbott reports third-quarter 2017 results.Sees FY 2017 gaap earnings per share $0.97 to $0.99 from continuing operations.Q3 adjusted earnings per share $0.66 from continuing operations.Q3 gaap earnings per share $0.32 from continuing operations.Q3 earnings per share view $0.65 -- Thomson Reuters I/B/E/S.Sees Q4 adjusted earnings per share $0.72 to $0.74 from continuing operations excluding items.Sees FY 2017 adjusted earnings per share $2.48 to $2.50 from continuing operations.Sees Q4 2017 gaap earnings per share $0.28 to $0.30 from continuing operations.Q3 sales $6.8 billion versus I/B/E/S view $6.72 billion.Abbott Laboratories - ‍narrowed its full-year 2017 eps guidance range​.Abbott Laboratories qtrly total pediatric sales $‍975​ million, up 0.8 percent on a reported basis.Abbott Laboratories qtrly total nutrition sales $1,768 million, up 0.8 percent on a reported basis‍​.Abbott Laboratories - qtrly total vascular sales $‍724​ million, up 17.1 percent on reported basis.Abbott Laboratories - qtrly total diagnostics sales $1,279 million, up 5.4 percent on a reported basis ‍​.Abbott Laboratories - ‍on Oct. 3, 2017, Abbott completed acquisition of Alere​.FY 2017 earnings per share view $2.50 -- Thomson Reuters I/B/E/S.Q4 earnings per share view $0.74 -- Thomson Reuters I/B/E/S.Abbott Laboratories - ‍expects to initiate launch of its alinity systems in U.S. In 2018​.  Full Article

Abbott Laboratories says ‍announced U.S. Launch of company's proclaim DRG neurostimulator system​
Monday, 16 Oct 2017 09:00am EDT 

Oct 16 (Reuters) - Abbott Laboratories ::Abbott laboratories - ‍announced U.S. launch of company's proclaim DRG neurostimulator system​.  Full Article

Abbott completes cash tender offer for Series B Convertible Perpetual Preferred Stock of Alere Inc
Wednesday, 4 Oct 2017 08:00am EDT 

Oct 4 (Reuters) - Abbott Laboratories :Abbott completes cash tender offer for Series B Convertible Perpetual Preferred Stock of Alere Inc..  Full Article

Abbott extends previous cash tender offer for outstanding Series B shares of Alere Inc
Monday, 2 Oct 2017 08:00am EDT 

Oct 2 (Reuters) - Abbott Laboratories :Abbott announces extension of cash tender offer for all outstanding shares of Series B convertible perpetual preferred stock of Alere Inc..Abbott Laboratories - offer to purchase all shares of Series B preferred stock of Alere will now expire at 11:59 p.m. New York City time on Tuesday, Oct. 3, 2017.  Full Article

BRIEF-Biogaia signs deal with Abbott to launch probiotic in China

* SAYS HAS SIGNED AN EXCLUSIVE AGREEMENT WITH ABBOTT FOR RIGHTS TO COMMERCIALIZE BIOGAIA PROTECTIS TABS IN CHINA